摘要
目的分析针对乙肝肝硬化患者应用恩替卡韦联合微生态制剂的临床治疗效果。方法选取2020年1月至2022年1月郑州大学第一附属医院收治的乙肝肝硬化患者300例进行观察,根据治疗方法差异,将应用恩替卡韦治疗的150例患者列为对照组,应用恩替卡韦联合微生态制剂治疗的150例患者列为观察组,分析对比不同治疗方法的治疗效果。结果观察组患者治疗后总有效率(94.66%)高于对照组(76.66%)(P<0.05)。两组患者治疗前临床症状发生率对比差异无统计学意义(P>0.05),治疗后观察组临床症状发生率指标显著低于对照组(P<0.05)。两组患者治疗前肝功能情况对比差异无统计学意义(P>0.05),治疗后观察组谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)指标显著高于对照组(P<0.05)。两组患者治疗前肝纤维化指标对比差异无统计学意义(P>0.05),治疗后观察组患者透明质酸(HA)、层黏蛋白(LN)、IV型胶原(IV-C)、Ⅲ型前胶原(PC-Ⅲ)指标均显著低于对照组(P<0.05)。两组患者治疗前脾脏厚度和门静脉内径对比差异无统计学意义(P>0.05),治疗后观察组患者脾脏厚度和门静脉内径均显著低于对照组(P<0.05)。两组患者在治疗后均未出现明显不良反应(P>0.05)。结论针对乙肝肝硬化患者应用恩替卡韦联合微生态制剂的临床治疗效果良好,值得推广应用。
Objective To analyze the therapeutic effect of Entecavir combined with microecological preparation on pa-tients with hepatitis B cirrhosis.Methods A total of 300 patients with hepatitis B cirrhosis admitted to our hospital from January 2020 to January 2022 were selected for observation.According to the differences in treatment methods,150 pa-tients treated with Entecavir were selected as the control group,and 150 patients treated with Entecavir combined with microecological preparation were selected as the observation group,and the therapeutic effects of different treatment methods were analyzed and compared.Results The total effective rate of observation group(94.66%)was higher than that of control group(76.66%)(P<0.05).There was no significant difference in the incidence of clinical symptoms between the two groups before treatment(P>0.05),and the incidence of clinical symptoms in the observation group was significantly lower than that of the control group after treatment(P<0.05).There was no significant difference in liver function between the two groups before treatment(P>0.05).After treatment,the indexes of ALT,AST and TBIL in the observation group were significantly higher than those of the control group(P<0.05).There was no significant difference in liver fibrosis indexes between the two groups before treatment(P>0.05).After treatment,the indexes of HA,LN,IV-C and PC-Ⅲin observation group were significantly lower than those of control group(P<0.05).There was no significant difference in spleen thickness and portal vein diameter between two groups before treatment(P>0.05).After treatment,spleen thickness and portal vein diameter in observation group were significantly lower than those of control group(P<0.05).There were no obvious adverse reactions in both groups after treatment(P>0.05).Conclusion Entecavir combined with microecological preparation has good therapeutic effect on patients with hepatitis B cirrhosis and is worthy of clinical application.
作者
谢颖
王滢革
赵勇娜
XIE Ying;WANG Ying-ge;ZHAO Yong-na(Department of the Second Ward of Infectious Diseases,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,China)
出处
《医药论坛杂志》
2023年第23期88-91,96,共5页
Journal of Medical Forum
关键词
恩替卡韦
微生态制剂
乙肝肝硬化
肝功能
肝纤维化
Entecavir
Microecological preparation
Hepatitis B cirrhosis
Liver function
Hepatic fibrosis
